iPS Academia Japan, Inc.

Sharing the fruits of iPS cell research
for the good of all humanity

Japanese

What's New

News room


License-In 2018/04/11

Summaries of 2 newly published patent applications are added to “Patent Portfolio”

We released the summaries of 2 newly published patent applications from our “Patent Portfolio” as follows.

AJ141  Compound for removing human pluripotent stem cells

AJ151  Method for producing serotonin neuron

Please find the details from each links above.

*We are not disclosing any summaries of unpublished patent applications. After their publication, we announce on “What’s New”, and release on “Patent Portfolio.”

Other 2018/03/29

Updated the “Patent Information”

New patent information relates to iPS cell technologies for the month of February 2018 has been updated.
Please see Patent Information for more details.
We have updated the page once a month.

License-Out 2018/03/15

License Agreement Has Been Entered with Platelet Biogenesis, Inc.

We executed a non-exclusive license agreement with Platelet Biogenesis, Inc. (Cambridge, U.S.A.) for the use of iPS cell-derived platelet products for human regenerative therapy, on the patents related to iPS cell technology that have been sublicensed to us by Kyoto University.

Platelet Biogenesis, Inc.

License-In 2018/03/12

License Agreement Has Been Entered with Kwansei Gakuin University

We have executed an exclusive license-in agreement with Kwansei Gakuin University as to their invention under a patent entitled “Method for DNA demethylation and use thereof (Inventor: SEKI Yoshiyuki)”. The invention provides a method for DNA demethylation in cells and a method for establishing high quality iPS cells by the use of PRDM14 and TET1. PRDM14 has been discovered by the inventor as a PR domain-containing transcriptional regulator which plays a crucial role in primordial germ cell development. Please contact us for its licensing.

Other 2018/02/27

Updated the “Patent Information”

New patent information relates to iPS cell technologies for the month of January 2018 has been updated.
Please see Patent Information for more details.
We have updated the page once a month.

License-Out 2018/02/19

License Agreement Has Been Entered with Stemnovate Ltd.

We executed a non-exclusive license agreement with Stemnovate Ltd. which provides services related to iPS cells for research use, on the patents related to the iPS cells technology that have been sublicensed to us by Kyoto University.

Stemnovate Ltd.

License-In 2018/02/13

Summaries of 4 newly published patent applications are added to “Patent Portfolio”

We released the summaries of 4 newly published patent applications from our “Patent Portfolio” as follows.

AJ146  Method for producing CD4/CD8 double-positive T cells

AJ147  Method for cell-specifically controlling nuclease

AJ148  RNA structure library

AJ149 Method for expressing protein gene in response to expression of miRNA

Please find the details from each links above.

*We are not disclosing any summaries of unpublished patent applications. After their publication, we announce on “What’s New”, and release on “Patent Portfolio.”

License-Out 2018/01/29

License Agreement Has Been Entered with Elpis Biomed Limited

We have executed a non-exclusive license agreement with Elpis Biomed Limited, under which Elpis generates iPS cell-derived, differentiated human cell types for research using its proprietary technology. We have granted Elpis a commercial license with regards to the patents covering the iPS cells technology that have been granted a sublicensing right to us by Kyoto University.

Elpis Biomed

Other 2018/01/17

Updated the “Patent Information”

New patent information relates to iPS cell technologies for the month of December 2017 has been updated.
Please see Patent Information for more details.
We have updated the page once a month.

License-Out 2018/01/12

License Agreement Has Been Entered between iPS Academia Japan, Inc. and myriamed GmbH

iPS Academia Japan, Inc.:

We executed a non-exclusive license agreement with myriamed GmbH, Germany which provides services in drug development using iPS cell-derived cells, on the patents related to the iPS cell technology that have been sublicensed to us by Kyoto University.

myriamed GmbH:

We are excited about the execution of a license agreement with iPS Academia Japan, Inc., and look forward to merging the exciting reprogramming technology originally developed by Nobel laureate Prof. Shinya Yamanaka with our proprietary phenotypic heart muscle screening platform.

myriamed GmbH

1 / 1012345...10...Last »